Recently Added

  • KISQALI® (ribociclib) sponsored by Novartis Pharmaceuticals Corporation


    NOVARTIS

    Kisqali Is Indicated For The Treatment Of Adult Patients With Hormone Receptor (Hr)-Positive, Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Advanced Or Metastatic Breast Cancer In Combination With: An Aromatase Inhibitor As Initial Endocrine-Based Therapy; Or Fulvestrant As Initial Endocrine-Based Therapy Or Following Disease Progression On Endocrine Therapy In Postmenopausal Women Or In Men.

  • Dupixent® (dupilumab) Injection by Regeneron and Sanofi Genzyme


    SANOFI-REGENERON

    Dupixent Is Indicated As An Add-On Maintenance Treatment In Patients With Moderate-To-Severe Asthma Aged 12 Years And Older With An Eosinophilic Phenotype Or With Oral Corticosteroid Dependent Asthma. Limitation Of Use: Dupixent Is Not Indicated For The Relief Of Acute Bronchospasm Or Status Asthmaticus.

  • LEQVIO® (inclisiran) injection, for subcutaneous use by Novartis Pharmaceuticals Corporation


    NOVARTIS

    Leqvio (Inclisiran) Injection Is Indicated As An Adjunct To Diet And Maximally Tolerated Statin Therapy For The Treatment Of Adults With Clinical Atherosclerotic Cardiovascular Disease (Ascvd) Or Heterozygous Familial Hypercholesterolemia (Hefh) Who Require Additional Lowering Of Low-Density Lipoprotein Cholesterol (Ldl-C). Limitations Of Use: The Effect Of Leqvio On Cardiovascular Morbidity And Mortality Has Not Been Determined.

  • NUCALA (mepolizumab) by GSK


    GLAXOSMITHKLINE

    Nucala Is An Interleukin-5 (Il-5) Antagonist Monoclonal Antibody (Igg1 Kappa) Indicated For: • Add-On Maintenance Treatment Of Adult And Pediatric Patients Aged 6 Years And Older With Severe Asthma And With An Eosinophilic Phenotype. • Add-On Maintenance Treatment Of Adult Patients 18 Years And Older With Chronic Rhinosinusitis With Nasal Polyps (Crswnp). • The Treatment Of Adult Patients With Eosinophilic Granulomatosis With Polyangiitis (Egpa). • The Treatment Of Adult And Pediatric Pat

  • TIBSOVO® (ivosidenib tablets) by Servier Pharmaceuticals


    AGIOS PHARMACEU

    Tibsovo Is An Isocitrate Dehydrogenase-1 (Idh1) Inhibitor Indicated For The Treatment Of Adult Patients With A Susceptible Idh1 Mutation As Detected By An Fda-Approved Test With: Acute Myeloid Leukemia (Aml) Newly-Diagnosed Aml Who Are = 75 Years Old Or Who Have Comorbidities That Preclude Use Of Intensive Induction Chemotherapy. Relapsed Or Refractory Aml. Locally Advanced Or Metastatic Cholangiocarcinoma Locally Advanced Or Metastatic Cholangiocarcinoma Who Have Been Previous